Hepatitis C: Epidemiology and review of complementary/alternative medicine treatments

Alternative Medicine Review

Volumn 4, Issue 4, 1999, Pages 220-238

  Patrick, Lyn ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ALPHA2 INTERFERON; ANTIOXIDANT; ANTIVIRUS AGENT; CATECHIN; GAMMA INTERFERON; GLYCYRRHETINIC ACID; GLYCYRRHIZIC ACID; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; NEOMINOPHAGEN C; PHYTOSTEROL; RIBAVIRIN; SILYMARIN; SPIRONOLACTONE;

ALTERNATIVE MEDICINE; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; HYPOKALEMIA; IMMUNOSTIMULATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LYMPHOCYTE PROLIFERATION; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYTOCHEMISTRY; REVIEW; T LYMPHOCYTE; VIRUS TRANSMISSION;

EID: 0032857259     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. World Health Organization. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997;10:65-72.
2. nd ed. London: Churchill Livingston; 1998:1-13.
3. Births and Deaths, Preliminary data for 1997. Natl Vital Stat Rep 1998;47:l-8. NIH Consensus Development Conference.
4. NIH Consensus Development Conference: Management of Hepatitis C. April 27, 1998. National Institutes of Health, Bethesda, Maryland.
5. Di Bisceglie AM, Order SE, Klein JK, et al. The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am J Gastoenterol 1991;86:335-338.
6. Lindsay KL. Therapy of hepatitis C: an overview. NIH Consensus Development Conference: Management of Hepatitis C. April 1998. National Institutes of Health, Bethesda, Maryland.
7. Carithers RL. Therapy of hepatitis C: Interferon Alfa-2B. NIH Consensus Development Conference: Management of Hepatitis C. April 1998. National Institutes of Health, Bethesda, Maryland.
8. Nishiguchi S, Kuroki R, Nakatani S, et al. Randomized trial of effects of interferon-alfa on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055.
9. McHutchinson JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Eng J Med 1998;339:1485-1492.
10. Sherman A. HCV on the threshold. Infect Med 1999;16:92-94.
11. Purcell R. The hepatitis C virus: overview. NIH Consensus Development Conference: Management of Hepatitis C. Hepatology 1997;26:11S-14S.
12. Mozzi F, Rebulla T, Locatelli E, et al. Antibody to hepatitis C virus in Italian thalassemics evaluated with second generation tests. Proceedings of the Third International Symposium on Hepatitis C Virus. Strasbourg, France 1991:90.
13. Locasciolli A, Gornati G, Tagger A, et al. Hepatitis C virus infection and chronic liver disease in children with leukemia in long term remission. Blood 1991;88:53-54.
14. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334:1685-1690.
15. nd ed. London: Churchill Livingston; 1998:319-338.
16. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin of disease. Hepatology 1994;19:13-18.
17. Yoshioka K, Kakumu S, Wakita T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992;16:293-299.
18. nd ed. London: Churchill Livingston; 1998:253-269.
19. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26:62S-65S.
20. Akahane Y, Kojima M, Sugai Y. Hepatitis C viral infection in spouses of patients with type C chronic liver disease. Ann Intern Med 1994;120:748-752.
21. Reinus JF, Leikin EL, Later HJ, et al. Failure to detect vertical transmission of hepatitis C virus. Ann Int Med 1992;117:881-886.
22. Conry-Cantilena C, VanRaden MA, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-1696.
23. Alter MJ. Epidemiology of hepatitis C in the west. Semin Liver Dis 1995;15:5-14.
24. Allander T, Gruber A, Naghavi M, et al. Frequent patient-to-patient transmission in a hematology ward. Lancet 1995;345:603-607.
25. Esteban JI, Gomez J, Martell M, et al. Transmission of hepatitis C virus by a cardiac surgeon. N Engl J Med 1996;334:555-560.
26. Dienstag JL. Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterol 1983;85:439-462.
27. McGaughan GW, McGuiness PH, Bishop GA, et al. Clinical assessment and incidence of hepatitis C RNA in 50 consecutive RIBA-positive volunteer blood donors. Med J Aust 1992;157:231-233.
28. Alter HJ, Purcell RH, Fienstone SM, et al. Non-A, non-B hepatitis: a review and interim report of an ongoing prospective study. In: Szmuners W, Alter HJ, Maynard JE, eds. Viral Hepatitis: 1981 International Symposium. Philadelphia, PA: Franklin Institute Press, 1982:359-369.
29. Kiyosawa K, Sodeyama T, Tanaka E, et al. Natural history of hepatitis C. Intervirology 1994;37:101-107.
30. Hoofnagle J. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26:15S-20S.
31. nd ed. London: Churchill Livingstone; 1998:309-318.
32. Prieto P, Plasp V, Verdu C, et al. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology 1995;22:413-417.
33. Mercan I, Sherlock S, McIntyre N, et al. Clinical, biochemical and histological features in 102 patients with chronic hepatitis C virus infection. Quart J Med 1993;86:119-125.
34. Agnello V, Chung RT, Kaplan LM. A role of hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992;327:1490-1495.
35. DeCastro M, Sanchez J, Herrera JF, et al. Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology 1992;16:231. [Abstract]
36. Sulkowski MS. Hepatitis C virus and HIV coinfection. CRIA Update 1998;8:15-18.
37. Watson HG, Zhang LQ, Simmons P, et al. Hepatitis C viral load increases with time after HIV infection. Int Conf AIDS 1992;July: 19-24; B195 (abstract # PoB 3629).
38. Darby SC, Ewart DW, Giagrande PLF, et al. Mortality from liver cancer and liver disease in hemophiliac men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350:1425-1431.
39. Nishioka K, Watanabe J, Furuta S, et al. A high prevalence of antibody to the hepatitis C virus with hepatocellular carcinoma in Japan. Cancer 1991;67:429-433.
40. Bruix J, Barrera JM, Calvet X, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989;28:1004-1006.
41. Bisceglie AM. Hepatitis C and hepatocellular carcinoma. NIH Consensus Development Conference: Management of Hepatitis C. Program and Abstracts. Office of the Director, National Institutes of Health. March 24, 1997. National Institutes of Health, Bethesda, Maryland.
42. Zoli M, Magalotti D, Bianchi G, et al. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996;78:977-985.
43. Levine R. Treating histologically mild chronic hepatitis C: monotherapy, combination therapy, or tincture of time? Ann Intern Med 1998;129:323-326.
44. Haber MM, West AB, Haber AD, et al. Relationship of aminotransferase to liver histological status in chronic hepatitis C. AM J Gastroenterology 1995;90:1250-1257.
45. Bedosa P, Poynard T. An algorithim for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-293.
46. Poynard T, Bedosa P, Opolon P. Natural history of lower fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
47. st ed. Seattle, WA: Hogrefe & Huber; 1997.
48. Scheuer PJ, Ashrefzadeh P, Sherlock S, et al. The pathology of hepatitis C. Hepatology 1992;15:567-571.
49. Bach N, Thung S, Schnafer F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992;15:572-577.
50. Gonzales-Peralta RP, Lau JYN. Pathogenic mechanisms for hepatocellular damage in chronic hepatitis C virus infection. Semin Gastro 1995;6:28-34.
51. Lim HL, Nelson DR, Fang JWS. The tumor necrosis factor-alpha system in chronic hepatitis C. Hepatology 1994;20:251A.
52. O'Garra A. Interleukins and the immune system 1. Lancet 1989;1:943-946.
53. Clerici M, Shearer GM. A TH1 to TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-111.
54. Personal communication; July 1999. Patrick Bouic, PhD, Dept. of Medical Microbiology, Medical Faculty, University of Stellenbosch, Tygerberg 7505, South Africa.
55. Lirussi F, Sanchez B, Pelizzari L, et al. Natural killer cells in patients with chronic hepatitis C (CHC). Gut 1998;42:A32.
56. Chemello L, Cavaletto L, Bernardinello E, et al. The effect of Interferon alfa and ribavirin combination therapy in naïve patients with chronic hepatitis C. J Hepatol 1995;23:S8-S12.
57. Reichard O, Yun Z-B, Sonnerborg A, et al. Hepatitis C viral RNA titers in serum prior to, during and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol 1993;41:99-102.
58. Di Bisceglie AM, Bacon BR, Kleiner DE, et al. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol 1994;21:1109-1112.
59. Dusheiko G, Main J, Thomas HC, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo controlled study. J Hepatol 1996;25:591-598.
60. Gane EJ, Su-Kong L, Riordan SM, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998;27:1403-1407.
61. Ning Q, Brown D, Parodo J. Ribavirin inhibits procoagulant activity and viral induced macrophage production of TNF and IL1, while preserving TH1 cytokine production and inhibiting TH2 cytokine response. Hepatology 1996;24:355A.
62. Salen G, Ahrens EH, Grundy AM. Metabolism of beta-sitosterol in man. J Clin Invest 1970;49:952-967.
63. Bouic PJD, Etsebeth RW, Liebenberg CF. Beta-sitosterol and beta-sitosterol glucoside stimulate human peripheral blood lymphocyte proliferation: implications for their use as an immunomodulatory vitamin combination. Int J Immunopharmac 1996;18:693-700.
64. Weihrach JL, Gardner JM. Sterol content of foods of plant origin. J Amer Diet Assoc 1978;73:39-47.
65. Yamamoto M, Matsui T, Sugiyama K, et al. Anti-inflammatory active constituents of Aloe arborescens Miller. Agric Biol Chem 1991;55:1627-1629.
66. Ivorra MD, D'Ocon MP, Paya M, et al. Antihyperglycemic and insulin releasing effects of beta-sitosterol 3-B-D-glucoside and its aglycone beta-sitosterol. Arch Int Pharmacodyn Ther 1988;296:224-231.
67. Carbin BE, Larsson B, Lindake O. Treatment of benign prostatic hyperplasia with phytosterols. B J Urol 1990;66:629-641.
68. Pegel KH. The importance of sitosterol and sitosterolin in human and animal nutrition. S Afr J Sci 1997;93:263-268.
69. Bouic PJD. Sterols/sterolins, nontoxic immunomodulators and their role in the control of rheumatoid arthritis. Newsletter of the Arthritis Trust of America; Summer 1998.
70. Bouic PJD. Immunomodulation in HIV/AIDS: The Tygerberg/Stellenbosch University Experience. AIDS Bulletin 1997;6:18-20.
71. Personal communication; July 1999. Patrick Bouic, PhD, Dept. of Medical Microbiology, Medical Faculty, University of Stellenbosch, Tygerberg 7505, South Africa.
72. Pinto HC, Baptista A, Camilo ME, et al. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996;41:172-179.
73. Letteron P, Fromenty B, Terris B, et al. Acute and chronic hepatitic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996;24:200-208.
74. MacSween RNM. Pathology of viral hepatitis and its sequelae. Clin Gastroenterol 1980;9:23-45.
75. Day CP, James OFW. Hepatic steatosis: innocent bystander or guilty party? Hepatology 1998;27:1463-1465.
76. Reeves HL, Burt AD, Wood S, et al. Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J Hepatol 1996;25:677-683.
77. Wenzel G, Kulinski B, Ruhlman C. Alcohol-induced toxic hepatitis - a free radical associated disease. Lowering fatality by adjuvant antioxidant therapy. Z Gesamte Inn Med 1993;48:490-496.
78. Reizis AR, Malinovskaia W, Shekhade S, et al. Effectiveness of using recombinant interferon alfa2 (reaferon) combined with antioxidants in children with acute hepatitis B. Pediatriia 1992; 1:60-64. [Article in Russian]
79. Beloqui O, Prieto J, Suarez M, et al. N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J Interferon Res 1993;13:279-282.
80. Hoglum K, Ventkataramani A, Lyche K, et al. A pilot study of the effects of d-alpha tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997;113:1069-1073.
81. Fujisawa K, Tandon BN. Therapeutic approach to the chronic active liver disease: Summary of a satellite symposium. In: Nishioka K, Suzuki H, Mishiro S, et al. eds. Viral Hepatitis and Liver disease. Tokyo: Springer; 1994:662-665.
82. Hattori M. Metabolism of glycyrrhizin by human intestinal flora II. Isolation and characterization of human intestinal bacteria capable of metabolizing glycyrrhizin and related compounds. Chem Pharm Bull 1985;33:210-217.
83. Nose M, Ito M, Kamimura K, et al. A comparison of the anti-hepatotoxic activity between glycyrrhizin and glycyrrhetinic acid. Planta Med 1994;60:136-139.
84. Abe N, Ebina T, Ishida N. Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice. Microbiol Immunol 1982;26:535-539.
85. Pompei R, Flore O, Marccialis MA, et al. Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature 1979;281:689-690.
86. Crance JM, Biziagos E, Passagot J, et al. Inhibition of hepatitis A virus replication in vitro by antiviral compounds. J Med Virol 1990;31:155-160.
87. Crance JM, Leveque F, Biziagos E, et al. Studies on the mechanism of action of glycyrrhizin against hepatitis A virus replication. Antiviral Res 1994;23:63-76.
88. Nagai T, Egashira T, Yamanaka Y, et al. Attenuation of dysfunction in the ischemia-reperfusion liver by glycyrrhizin. Arch Environ Contain Toxicol 1991:20;432-436.
89. Kimura M, Watanabe H, Abo T. Selective activation of extrathymic T cells in the liver by glycyrrhizin. Biotherapy 1992;5:167-176.
90. Suzuki H, Ohta Y, Takino T, et al. The therapeutic effects of Stronger Neo Minophagen C for chronic hepatitis. Igaku no Ayumi 1977;102:562-568.
91. Hino K, Miyakawa H, Kondo T, et al. Effects of glycyrrhizin therapy on liver histology in chronic aggressive hepatitis. In: Shikata T, Purcell RH, Uchida T, eds. Viral Hepatitis C, D, and E. Amsterdam: Excerpta Medica; 1987:295-303.
92. Yasuda K, Hino K, Fujioka S, et al. Effects of a high dose therapy with Stronger Neo Minophagen C (SNMC) on hepatic histography in non-A, non-B chronic active hepatitis. In: Shikata T, Purcell RH, Uchida, eds. Viral Hepatitis C, D, and E. Amsterdam: Excerpta Medica; 1991:205-209.
93. Hoofnagle JH, Lau D, Conjeervaram H, et al. Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepatitis 1996;3:247-252.
94. Arase Y, Ikeda K, Murashima N. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79:1494-1500.
95. Xianshi S, Huiming C, Lizhuang W, et al. Clinical and laboratory observation on the effect of glycyrrhizin in acute and chronic viral hepatitis. J Tradit Chin Med 1984;4:127-132.
96. Perissoud D, Weibel I. Protective effect of (+)-cyanidanol-3 in acute liver injury induced by gaiactosamine or carbon tetrachloride in the rat. Naunyn Schmiedeberg's Arch Pharmacol 1980;312:285-291.
97. Balant L. Clinical pharmacology of (+)-cyanidanol-3: a synopsis with emphasis on pharmacokinetics. In: Conn HO, ed International Workshop on (+)-Cyanidanol-3 in Liver Diseases. London: The Royal Society of Medicine; 1981:49-54.
98. Colman C, Morgan MY, Scheur PJ, et al. Treatment of alcohol-related liver disease with (+)-cyanidanol-3: a randomised double-blind trial. Gut 198;21:965-969.
99. World MJ, Aps EJ, Shaw GK, Thomson AD. (+)-Cyanidanol-3 for alcoholic liver disease: results of a six-month clinical trial. Alcohol Alcohol 1984;19:23-29.
100. Piazza M, Guadagnino V, Picciotto G, et al. Effect of (+)-cyanidanol-3 in acute HAV, HB V, and non-A, non-B viral hepatitis. Hepatology 1983;3:45-49.
101. Blum AL, Doelle W, Kortum K, et al. Treatment of acute viral hepatitis with (+)-cyanidanol-3. Lancet 1977;2:1153-1155.
102. Di Nola F. (+)-Cyanidanol-3 in acute viral hepatitis. Lancet 1980;2:1379-1380.
103. Piazza M, de Mercator R, Guadagnino V, et al. Effect of (+)-cyanidnaol-3 on chronic persistent or chronic active hepatitis. In: Conn HO, ed. International Workshop on (+)-Cyanidanol 3 in Diseases of the Liver. London: The Royal Society of Medicine; 1981:123-129.
104. Loginov AS, Dzhalalov KD, Blok IuE, et al. Treatment of chronic diseases of the liver with catergen. Ter Arkh 1986;58:73-76. [Article in Russian]
105. Suzuki H, Yamamato S, Hirayama C. Cianidanol therapy for Hbe-antigen-positive chronic hepatitis: a multicentre, double-blind study. Liver 1986;6:35-44.
106. Salama A, Mueller-Eckhardt C. Cianidanol and its metabolites bind tightly to red cells and are responsible for the production of auto- and/ or drug-dependent antibodies against these cells. Br J Haematol 1987;66:263-266.
107. Gandolfo GM. Hemolytic anemia and thromb-ocytopenia induced by cyanidanol. Acta Haematol 1992;88:96-99.
108. Luper S. A review of plants used in the treatment of liver disease: Part 1. Altern Med Rev 1998;3:410-421.
109. Gagliardi B, Fiori GP. Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centers. Med Klin 1978;73:1060-1065.
110. Moscarelli S, Guisti A, Marra F, et al. Therapeutic and anti-lipoperoxidant effects of silybin-phosphatidylcholine complex in chronic liver disease: preliminary results. Curr Ther Res 1993;53:98-102.
111. Vailaii A, Arista I, Sozze E, et al. Randomized open study of the dose-effect relationship of a short course of WB1016 in patients with viral or alcoholic hepatitis. Fitoterapia 1993;64:219-228.
112. Mehrotra R, Rawat S, Kulshreshtha DK, et al. In vitro studies on the effect of certain natural products against hepatitis B virus. Indian J Med Res 1990;92:133-138.
113. Jayaram S, Thyagarajan SP. Inhibition of HBsAg secretion from Alexander cell line by Phyllanthus amarus. Indian J Pathol Microbiol 1996;39:211-215.
114. Ott M, Thyagarajan SP, Gupta S. Phyllanthus amarus suppresses hepatitis B virus by interrupting interactions between HBV enhancer I and cellular transcription factors. Eur J Clin Invest 1997;27:908-915.
115. Wang M, Cheng H, Li Y, et al. Herbs of the genus Phyllanthus in the treatment of chronic hepatitis B: observations with three preparations from different geographic sites. J Lab Clin Med 1995;126:350-352.
116. Thamlikitkul V, Wasuwat S, Kanchanapee P. Efficacy of Phyllanthus amarus for eradication of hepatitis B virus in chronic carriers. J Med Assoc Thai 1991;74:381-385.
117. Milne A, Hopkirk N, Lucas CR, et al. Failure of New Zealand hepatitis B carriers to respond to Phyllanthus amarus. N Z Med J 1994;107:243.
118. Kann M, Gerlich W. Structure and molecular virology. In: Zuckerman AJ, Thomas HC, eds. Viral Hepatitis. London: Churchill Livingston; 1998:77-99.
119. Thomas HC, Thurz MR. Pathogenesis of chronic hepatitis B. In: Zuckerman AJ, Thomas HC, eds. Viral Hepatitis. London: Churchill Livingston; 1998.
120. Main J, Thomas HC. Treatment of chronic hepatitis B. In: Zuckerman AJ, Thomas HC, eds. Viral Hepatitis. London: Churchill Livingston;1998.